Teva Pharmaceuticals Announces Promising Mid-Stage Trial Results for Celiac Disease Drug
Translated & summarized from Now 14 by baba
Teva Pharmaceuticals has reported positive Phase 2a trial results for its experimental celiac disease drug, TEV-408, which significantly protected the small intestine from gluten damage. The company also sees potential for the drug in treating vitiligo, and the news boosted its stock price.
The story in 5 lines · by baba
- Teva's experimental drug TEV-408 showed significant promise in a mid-stage trial for celiac disease.
- The drug successfully protected the small intestine from gluten-induced damage in trial participants.
- TEV-408 is also being explored for potential treatment of vitiligo.
- Positive trial results led to a notable increase in Teva's stock value.
- Currently, there is no approved drug treatment for celiac disease.
Israeli pharmaceutical giant Teva announced on Wednesday positive results from its Phase 2a clinical trial for TEV-408, an experimental drug designed to treat celiac disease. The trial involved 50 adults with celiac disease who received a single dose of TEV-408. Following the dose, participants underwent a six-week "gluten challenge," consuming gluten daily to assess the drug's protective effects on the small intestine.
The study met its primary endpoint, demonstrating that TEV-408 significantly prevented gluten-induced damage to the small intestine compared to a placebo, with both statistical and clinical significance. The drug also showed positive impacts on intestinal inflammation markers and digestive symptoms. Teva reported that the drug was well-tolerated, with no new safety concerns identified.
If TEV-408 continues to show positive results in later development stages and gains regulatory approval, it could represent a major breakthrough for celiac disease patients, as there is currently no approved drug treatment, and the standard management is a strict gluten-free diet. Teva also believes TEV-408 has potential applications for treating vitiligo, an autoimmune skin condition, and is planning to advance the drug to a Phase 2b trial for this indication.
The announcement led to a significant increase in Teva's stock price, with shares jumping up to 4% on the Tel Aviv Stock Exchange and in early New York trading. While Teva's stock has experienced a strong upward trend in recent years, rising over 80% in the past year and nearly 300% in the last five years, it remains considerably below its 2015 peak.
The same event, reported separately by each outlet. Open a few to compare what different newsrooms emphasize — and what they leave out.
Left 1Centre 5Right 2Other 7
Not the same event — other stories that share this one’s people, places, or theme: background, reactions, and follow-ups.